Showing results (51-60 of 85) with videos related to
Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2021
RAS interaction with Sin1 is dispensable for mTORC2 assembly and activityPau Castel, Srisathiyanarayanan Dharmaiah, Matthew J Sale, et al.Science Translational Medicine|June 4, 2025
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancersYanyan Cai, Peihua Zhao, Fan Wu, et al.Science (New York, N.Y.)|September 11, 2025
Structural basis for LZTR1 recognition of RAS GTPases for degradationSrisathiyanarayanan Dharmaiah, Daniel A Bonsor, Stephanie P Mo, et al.Research Square|May 3, 2023
ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaVito Rebecca, Kasturee Jagirdar, Marie Portuallo, et al.British Journal of Cancer|June 20, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agentsPaola Roa, Valentina Foglizzo, Guilherme Harada, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 29, 2024
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatmentAntonino Glaviano, Seth A Wander, Richard D Baird, et al.Science Advances|July 14, 2023
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophyAntonio Cuevas-Navarro, Morgan Wagner, Richard Van, et al.Cancer Research|July 11, 2025
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung AdenocarcinomaAlessandro M Mozzarelli, Antonio Cuevas-Navarro, Emily G Shuldiner, et al.Oncogene|December 8, 2023
ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanomaKasturee Jagirdar, Marie E Portuallo, Meihan Wei, et al.Science (New York, N.Y.)|November 9, 2019
Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitorsNeil Vasan, Pedram Razavi, Jared L Johnson, et al.Pageof 9